Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland [0.03%]
瑞士儿童药物的药理遗传学推荐使用状况
Nina L Wittwer,Christoph R Meier,Carola A Huber et al.
Nina L Wittwer et al.
Pharmacogenetics (PGx) is increasingly implemented in the adult population, but its potential in children remains uncertain. The aim of this study was to investigate PGx drug utilization in children in Switzerland, using Helsana claims data...
Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States [0.03%]
在美国常见健康状况下分析药物基因组学的成本效益和节省费用
Mayuri S Patel,Emily J Cicali,Frank A Orlando
Mayuri S Patel
This review describes healthcare cost effectiveness/savings for pharmacogenetics (PGx) and relevant clinical outcomes in selected common health conditions. PGx allows targeted drug treatment based on genotype and phenotype. Studies highligh...
Ben L Kong,Benjamin G Brown,Victoria M Pratt et al.
Ben L Kong et al.
CYP2C19 point-of-care testing: where are we now and where should we go? [0.03%]
CYP2C19床旁检验：我们目前处于什么位置？我们应该何去何从？
Leticia A Shea
Leticia A Shea
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review [0.03%]
遗传生物标志物对儿童癌症幸存者心脏疾病的影响：系统评价研究
Naïla Aba,Claire Ducos,Eric Morel et al.
Naïla Aba et al.
Childhood cancer survivors (CCS) often suffer from cardiac disease (CD) after treatment that included anthracycline and radiotherapy involving the heart. However, the variability in CD occurrence cannot be explained solely by these treatmen...
KHSRP promotes the malignant behavior and cisplatin resistance of bladder cancer cells through the CLASP2/MAPRE1 axis [0.03%]
KHSRP通过CLASP2/MAPRE1轴促进膀胱癌细胞的恶性行为和顺铂耐药性
Ruizhe Wang,Cheng Zhao,Zhenyu Ou et al.
Ruizhe Wang et al.
Bladder cancer (BC) is a highly prevalent form of cancer worldwide, and cisplatin (CDDP) resistance poses a major challenge to patients. Cytoplasmic linker-associated protein 2 (CLASP2) is a member of the microtubule plus-end tracking prote...
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services [0.03%]
基于CYP2C19的氯吡格雷治疗实施：药理基因组学检测服务综述
Tark J Patel,Eman Wehbe,Stephen Hughes et al.
Tark J Patel et al.
Pharmacogenomic testing for CYP2C19 helps personalise clopidogrel therapy and reduces the risk of experiencing a secondary myocardial infarction in individuals with impaired CYP2C19 function. Routine testing, however, is uncommon and it is ...
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach [0.03%]
探索基因组学方法在坦桑尼亚镰状细胞病患者中影响羟基脲反应的药物基因组因素
Siana Nkya,Collin Nzunda,Emmanuel Saukiwa et al.
Siana Nkya et al.
In sub-Saharan Africa, sickle cell disease (SCD) remains a significant public health challenge. Despite the discovery of SCD over a century ago, progress in developing and accessing effective treatments has been limited. Hydroxyurea is the ...
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort [0.03%]
药理基因与重度抑郁障碍治疗效果的关系——来自撒丁岛队列的结果
Pasquale Paribello,Mirko Manchia,Marco Pinna et al.
Pasquale Paribello et al.
We examined the association of selected candidate pharmacodynamic (PD) genes in MDD with treatment outcomes, defined according to remission thresholds for Hamilton Depression Rating Scale (HDRS) with 6- and 17- items. To this end, we recrui...
Similarity of drug targets to human microbiome metaproteome promotes pharmacological promiscuity [0.03%]
靶标与人体微生物组的相似性促进药物多靶性
Christopher A Beaudoin,Shannon Norget,Ziad Omran et al.
Christopher A Beaudoin et al.
Similarity between candidate drug targets and human proteins is commonly assessed to minimize the occurrence of side effects. Although numerous drugs have been found to disrupt the health of the human microbiome, no comprehensive comparison...